The Advisory Committee on Immunization Practices (ACIP) has approved its immunization schedule for children and adolescents aged ≤18 years in the US, which summaries ACIP recommendations, including several changes from the 2016 immunization schedules. Changes include new or revised ACIP recommendations for influenza; human papillomavirus (HPV); hepatitis B (HBV); Haemophilus influenza type B; pneumococcal, meningococcal; and diphtheria and tetanus toxoids and acellular pertussis vaccines.

Among the changes to the 2017 figure:

Figure 1:

• The 16-year age column has been separated from the 17–18-year age column to highlight the need for a meningococcal conjugate vaccine booster dose at age 16 years.
• Live attenuated influenza vaccine (LAIV) has been removed from the influenza row.
• A blue bar was added for human papillomavirus vaccine (HPV) for children aged 9–10 years, indicating that persons in this age group may be vaccinated (even in the absence of a high-risk condition).

Figure 3:

A new figure, Figure 3, “Vaccines that might be indicated for children and adolescents aged 18 years or younger based on medical indications,” has been added. The purpose of this figure is the following:

• Demonstrate most children with medical conditions can (and should) be vaccinated according to the routine child/ adolescent immunization schedule.
• Indicate when a medical condition is a precaution or contraindication to vaccination.
• Indicate when additional doses of vaccines may be necessary because of a child’s or adolescent’s medical condition. Providers should consult the relevant footnotes for additional information.